Clinical trials
Completed Hypertension trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
70 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 3 |
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 6 |
| 2007 | 6 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 7 |
| 2012 | 6 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 70 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 10 |
| Novartis Pharmaceuticals | 10 |
| Sanofi | 7 |
| National Taiwan University Hospital | 4 |
| AstraZeneca | 3 |
| Chang Gung Memorial Hospital | 3 |
| Chung Shan Medical University | 3 |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | 3 |
| TSH Biopharm Corporation Limited | 3 |
| National Taipei University of Nursing and Health Sciences | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension | 70 |
| Essential Hypertension | 5 |
| Cardiovascular Diseases | 4 |
| Diabetes Mellitus, Type 2 | 4 |
| Metabolic Syndrome | 4 |
| Diabetes Mellitus | 3 |
| Dyslipidemias | 3 |
| Obesity | 3 |
| Renal Insufficiency, Chronic | 3 |
| Diabetic Nephropathies | 2 |
Trials
Showing 1 to 25 of 70. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.